Revolution Medicines: 1st patient dosed in RMC-6236 study for PDAC treatment

Revolution Medicines (RVMD) announced that the first patient has been dosed in RASolute 302, a Phase 3 registrational study of RMC-6236, a RAS multi-selective inhibitor, in patients with previously treated, metastatic pancreatic ductal adenocarcinoma PDAC …”Treating the first patient in RASolute 302 is a significant milestone for Revolution Medicines as we seek to revolutionize treatment for patients with RAS-addicted cancers,” said Mark A. Goldsmith M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. “RMC-6236 is designed to directly inhibit RAS(ON) signaling, which is the primary oncogenic driver of pancreatic cancer. Supported by the encouraging initial PFS and OS observations and safety profile reported from the Phase 1 RMC-6236 monotherapy trial, the randomized RASolute 302 trial will formally assess the potential for this bold investigational drug to make a meaningful difference for people living with metastatic PDAC, one of the most difficult-to-treat cancers.”